Weight- and Health-Related Quality of Life (WRQoL and HRQoL) with Canagliflozin (CANA) Versus Sitagliptin (SITA) in Subjects with Type 2 Diabetes Mellitus (T2DM) on Background Metformin
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.716
https://www.valueinhealthjournal.com/article/S1098-3015(13)02621-1/fulltext
Title :
Weight- and Health-Related Quality of Life (WRQoL and HRQoL) with Canagliflozin (CANA) Versus Sitagliptin (SITA) in Subjects with Type 2 Diabetes Mellitus (T2DM) on Background Metformin
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02621-1&doi=10.1016/j.jval.2013.08.716
First page :
A448
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
694